According to Zhitong Finance App News, Teda Biotech (08189.HK) announced that for the six months ending June 30, 2026, the Group expects to obtain: revenue of about RMB 290 million to RMB 300 million, an increase of about 28% to 33% over revenue for the six months ending June 30, 2025 (same period last year); and net profit attributable to company owners of about RMB 7 million to RMB 10 million, an increase of about 209% to 256% over the same period last year. Loss becomes profit.

According to Zhitong Finance App News, Teda Biotech (08189.HK) announced that for the six months ending June 30, 2026, the Group expects to obtain: revenue of about RMB 290 million to RMB 300 million, an increase of about 28% to 33% over revenue for the six months ending June 30, 2025 (same period last year); and net profit attributable to company owners of about RMB 7 million to RMB 10 million, an increase of about 209% to 256% over the same period last year. Loss becomes profit.